Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (UTHR) delivers innovative therapies for pulmonary arterial hypertension and rare diseases through cutting-edge research and targeted drug development. This news hub provides investors, healthcare professionals, and stakeholders with timely updates on regulatory milestones, clinical trial progress, and strategic initiatives shaping the biopharmaceutical landscape.
Access verified press releases, financial disclosures, and scientific advancements in one centralized location. Our curated collection features updates on treprostinil-based treatments, FDA approvals, partnership announcements, and R&D pipeline developments – all essential for tracking UTHR's progress in addressing unmet medical needs.
Discover comprehensive coverage spanning earnings reports, manufacturing expansions, and therapeutic innovations. Content is rigorously vetted to ensure accuracy and relevance for both expert analysts and general readers seeking reliable information about this biotechnology leader.
Bookmark this page for streamlined access to United Therapeutics' latest developments. Check back regularly to stay informed about critical updates impacting patient care and investment considerations in the specialized pharmaceutical sector.
United Therapeutics (UTHR) has announced its participation in the American Thoracic Society (ATS) International Conference in San Francisco, May 16-21, 2025, where it will present clinical data across its commercial and development portfolio.
Key presentations include interim long-term data from the ralinepag phase 3 ADVANCE EXTENSION open-label study and preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis. The company will showcase research through various sessions, including thematic posters, mini-symposia, and discussion sessions.
The company is also sponsoring several events including the Respiratory Innovation Summit, the ATS Research Program Benefit Networking Event, and hosting the Jenesis Innovative Research Awards™ Ceremony.
United Therapeutics (NASDAQ: UTHR) has announced it will release its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.
The webcast will be available through the company's investor relations website and will remain accessible for replay for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
United Therapeutics (UTHR) announced the presentation of ten posters and presentations across its commercial and development portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting taking place April 27-30, 2025 in Boston.
The presentations cover various topics including xenotransplantation developments, pharmacokinetic studies of Ralinepag, cardiac xenotransplantation outcomes, and pulmonary hypertension research. Key highlights include studies on multi-gene-edited pig lungs, pig-to-baboon lung transplantation, and safety data on low-dose oral Treprostinil in PH-HFpEF patients.
The company will also host a sponsored symposium titled 'The Pros, The Cons, the Wicked Good EVLP Debates' featuring experts from leading medical institutions discussing ex vivo lung perfusion.
United Therapeutics (NASDAQ: UTHR) has been recognized as one of the Fortune 100 Best Companies to Work For in 2025, ranking #73 on the prestigious list. The recognition comes from Great Place to Work® and Fortune magazine, based on confidential feedback from over 1.3 million U.S. employees.
As the first publicly-traded biotech company to become a public benefit (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and expanding transplantable organ availability. The company's placement on the list reflects its commitment to creating a high-trust workplace environment, measured through Great Place To Work's Trust Index™ Survey.
Michael Benkowitz, President & COO, emphasized the company's goal of being a destination employer, while Alyssa Friedrich, EVP and Chief People Officer, highlighted their focus on creating an environment where employees feel valued and inspired.
United Therapeutics (UTHR) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025 in Miami Beach. CFO James Edgemond will present a company update in a fireside chat on March 11, 2025, from 10:00-10:30 AM EDT.
The session will be accessible through a live webcast on the company's investor relations website, with a recorded version available for 90 days afterward. United Therapeutics, notably the first publicly-traded biotech/pharmaceutical public benefit (PBC), focuses on two main objectives:
- Developing novel pharmaceutical therapies
- Creating technologies to expand transplantable organ availability
United Therapeutics (UTHR) reported strong financial results for Q4 and full year 2024, with annual revenues reaching a record $2.88 billion, representing 24% growth over 2023.
The company's Tyvaso product line led growth with total revenues of $1.62 billion in 2024, up 31% from 2023. This growth was primarily driven by Tyvaso DPI's increased patient adoption and enhanced commercial utilization following Part D redesign under the Inflation Reduction Act.
Key clinical developments include: fully enrolled TETON studies in idiopathic pulmonary fibrosis with data expected in H2 2024, upcoming ralinepag data in 2025, and FDA clearance for the first potential registration-enabling xenotransplantation study with UKidney. The company also completed a $1 billion accelerated share repurchase program in 2024, resulting in 3,547,374 shares repurchased.
United Therapeutics (UTHR) has announced that President and COO Michael Benkowitz will present at the TD Cowen 45th Annual Health Care Conference in Boston. The fireside chat session is scheduled for March 3, 2025, from 1:50 p.m. to 2:20 p.m. EST.
The presentation will be accessible through a live webcast on the company's website, with a recorded version available for 90 days afterward. United Therapeutics, operating as a public benefit (PBC), focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
The company emphasizes its unique position as the first publicly-traded biotech/pharmaceutical PBC, highlighting its commitment to innovation for unmet medical needs while maintaining a dual focus on patient care and stakeholder benefits.
United Therapeutics (UTHR) has announced it will release its fourth quarter and full year 2024 financial results before market open on Wednesday, February 26, 2025. The detailed quarterly results will be published via press release at approximately 6:30 a.m. Eastern Time.
The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, which will be accessible through United Therapeutics' investor relations website. A replay of the webcast will remain available for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study, evaluating Tyvaso® (treprostinil) for treating idiopathic pulmonary fibrosis (IPF). The study enrolled 598 patients and is part of a three-study global TETON program, which includes TETON 2 (completed enrollment in July 2024) and TETON PPF (ongoing).
The program was initiated following promising results from the INCREASE study, which showed significant improvements in forced vital capacity (FVC) at weeks 8 and 16, particularly in IPF patients. Top-line data for TETON 1 is expected in first half of 2026, while TETON 2 results are anticipated in second half of 2025.
If successful, United Therapeutics plans to file for FDA approval to add IPF to Tyvaso's labeled indications and work with Grupo Ferrer Internacional for EMA marketing authorization.
United Therapeutics (NASDAQ: UTHR) has received FDA clearance for its Investigational New Drug (IND) application to begin clinical trials of UKidney™, a xenotransplantation organ derived from 10 gene-edited source pigs. This marks the first-ever human clinical trial of a xeno-organ intended for potential registration through a Biologics License Application.
The trial will initially enroll six end-stage renal disease (ESRD) patients, with plans to expand to 50 participants. The first xenotransplant is expected around mid-year 2025. The study targets two groups: ESRD patients ineligible for conventional kidney transplants and those on waitlists with high mortality risks.
According to the American Kidney Fund, over 557,000 U.S. patients require dialysis, with a 2009 study showing 52% of kidney transplant candidates aged 60+ die within five years before receiving a transplant. The company aims to provide an alternative to lifetime dialysis through xenotransplantation.
